153 related articles for article (PubMed ID: 30920187)
1. Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence.
Weiss RD; Griffin ML; Marcovitz DE; Hilton BT; Fitzmaurice GM; McHugh RK; Carroll KM
J Clin Psychiatry; 2019 Mar; 80(2):. PubMed ID: 30920187
[TBL] [Abstract][Full Text] [Related]
2. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
[TBL] [Abstract][Full Text] [Related]
3. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
[TBL] [Abstract][Full Text] [Related]
4. The Prescription Opioid Addiction Treatment Study: What have we learned.
Weiss RD; Rao V
Drug Alcohol Depend; 2017 Apr; 173 Suppl 1(Suppl 1):S48-S54. PubMed ID: 28363320
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.
Weiss RD; Potter JS; Griffin ML; Provost SE; Fitzmaurice GM; McDermott KA; Srisarajivakul EN; Dodd DR; Dreifuss JA; McHugh RK; Carroll KM
Drug Alcohol Depend; 2015 May; 150():112-9. PubMed ID: 25818060
[TBL] [Abstract][Full Text] [Related]
6. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
Worley MJ; Heinzerling KG; Shoptaw S; Ling W
Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
[TBL] [Abstract][Full Text] [Related]
7. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
8. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
9. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
10. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
[TBL] [Abstract][Full Text] [Related]
11. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava A; Kahan M; Nader M
Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
[TBL] [Abstract][Full Text] [Related]
12. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
Worley MJ; Shoptaw SJ; Bickel WK; Ling W
Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
[TBL] [Abstract][Full Text] [Related]
14. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
15. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
[TBL] [Abstract][Full Text] [Related]
16. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain.
Griffin ML; McDermott KA; McHugh RK; Fitzmaurice GM; Jamison RN; Weiss RD
Drug Alcohol Depend; 2016 Jun; 163():216-21. PubMed ID: 27161860
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.
Griffin ML; Dodd DR; Potter JS; Rice LS; Dickinson W; Sparenborg S; Weiss RD
Am J Drug Alcohol Abuse; 2014 Mar; 40(2):157-62. PubMed ID: 24219166
[TBL] [Abstract][Full Text] [Related]
19. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
Klein AA; Seppala MD
J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
